TY - JOUR T1 - Is there a serum proteome signature to predict mortality in severe COVID-19 patients? JF - medRxiv DO - 10.1101/2021.03.13.21253510 SP - 2021.03.13.21253510 AU - Franziska Völlmy AU - Henk van den Toorn AU - Riccardo Zenezini Chiozzi AU - Ottavio Zucchetti AU - Alberto Papi AU - Carlo Alberto Volta AU - Luisa Marracino AU - Francesco Vieceli Dalla Sega AU - Francesca Fortini AU - Gianluca Campo AU - Marco Contoli AU - Savino Spadaro AU - Paola Rizzo AU - Albert J.R. Heck Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/13/2021.03.13.21253510.abstract N2 - Here we recorded serum proteome profiles of 33 COVID-19 patients admitted to respiratory and intensive care units because of respiratory failure. We received, for most patients, blood samples just after admission and at two more later timepoints. We focused on serum proteins different in abundance between the group of survivors and non-survivors and observed that a rather small panel of about a dozen proteins were significantly different in abundance between these two groups. The four structurally and functionally related type-3 cystatins AHSG, FETUB, HRG and KNG1 were all more abundant in the survivors. The family of inter-α-trypsin inhibitors, ITIH1, ITIH2, ITIH3 and ITIH4, were all found to be differentially abundant in between survivors and non-survivors, whereby ITIH1 and ITIH2 were more abundant in the survivor group and ITIH3 and ITIH4 more abundant in the non-survivors. ITIH1/ITIH2 and ITIH3/ITIH4 also did show opposite trends in protein abundance during disease progression. This panel of eight proteins, complemented with a few more, may represent a panel for mortality risk assessment and eventually even for treatment, by administration of exogenous proteins possibly aiding survival. Such administration is not unprecedented, as administration of exogenous inter-α-trypsin inhibitors is already used in the treatment of patients with severe sepsis and Kawasaki disease. The mortality risk panel defined here is in excellent agreement with findings in two recent COVID-19 serum proteomics studies on independent cohorts, supporting our findings. This panel may not be unique for COVID-19, as some of the proteins here annotated as mortality risk factors have previously been annotated as mortality markers in aging and in other diseases caused by different pathogens, including bacteria.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04343053Funding StatementWe acknowledge support from the Dutch Research Council (NWO) funding the Netherlands Proteomics Centre through the X-omics Road Map program (project 184.034.019) and the EU Horizon 2020 program INFRAIA project Epic-XS (Project 823839).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the corresponding Ethics Committee (Comitato Etico di Area Vasta Emilia Centro, Bologna, Italy). All patients gave their written informed consent. In case of unconsciousness, the informed consent was signed by the next of kin or legal authorized representative. The study is registered at www.clinicaltrials.gov with the identifier NCT04343053.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe mass spectrometric proteomics data have been deposited at the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD024707. http://www.ebi.ac.uk/pride ER -